“…Pre-clinical studies of human tumor cultures and murine xenograft models using single-agent AZD1152 have been conducted in numerous tumor types, including breast61,62, pancreas62, colorectal62,63,64,65,66, non-small cell lung63,64, small cell lung67, hepatocellular carcinoma68, malignant mesothelioma69, AML62,70,71,72, and multiple myeloma (MM)73. AZD1152 is also a potent FLT3 inhibitor, potentially adding a dual mechanism to the antitumor effects in AML 74.…”